ChromaDex, Thorne Enter Marketing Deal for Niagen

IRVINE, Calif.ChromaDex Corp.® announced a three-year marketing deal with Thorne Research Inc. for ChromaDex's recently launched Niagen, its branded nicotinamide riboside (NR) ingredient.

Thorne Research will receive Niagen marketing rights for use in nutritional supplements in the United States and Canada. ChromaDex will receive a royalty on sales from Thorne Research products containing Niagen. In addition, Thorne Research will collaborate with ChromaDex on future human clinical trials of Niagen.

"Mitochondrial energy production is critical for efficient metabolism of fats and carbohydrates, weight management, athletic performance, cardiovascular health and neuroprotection," said Robert Rountree, M.D., chief medical officer of Thorne Research. "Research has shown that oral NR, a compound naturally found in the diet, can significantly optimize mitochondrial function by increasing intracellular levels of NAD+. Studies have shown that NR increases muscle endurance, protects nerve cells from injury, improves insulin sensitivity, lowers serum cholesterol and limits diet-induced obesity."

Niagen is the only commercially available brand of NR. During the past two years, ChromaDex has acquired patent rights from Cornell University, Dartmouth College and Washington University.

A recent study on NR validates the supplement's ability to cut obesity risk.